康方生物自主研发的新一代抗CD47人源化IgG4单克隆抗体莱法利单抗(AK117),获FDA授予的孤儿药资格认定,用于治疗急性髓系白血病(AML)。孤儿药资格认定将助力该药物在美国的后续研发及商业化,包括享受税收减免、免除申请费、获得研发资助及7年市场独占权等。目前,康方生物围绕莱法利单抗在血液肿瘤和实体瘤领域的临床开发均处于国际领先阶段,除AML外,较高危骨髓增生异常综合征(HR-MDS)的临床...
Source Link康方生物自主研发的新一代抗CD47人源化IgG4单克隆抗体莱法利单抗(AK117),获FDA授予的孤儿药资格认定,用于治疗急性髓系白血病(AML)。孤儿药资格认定将助力该药物在美国的后续研发及商业化,包括享受税收减免、免除申请费、获得研发资助及7年市场独占权等。目前,康方生物围绕莱法利单抗在血液肿瘤和实体瘤领域的临床开发均处于国际领先阶段,除AML外,较高危骨髓增生异常综合征(HR-MDS)的临床...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.